PRMT5 Knockout THP-1 Cell Pool

热销产品

undefined
undefined
+
  • undefined
  • undefined

编号 :

LM01300100462

产品编号: LM01300100462

市场价

销售价格:  ¥ 5499

数量
-
+

库存剩余

联系我们订购

抗体定制服务咨询

隐藏域元素占位

  • 产品描述
  • 细胞复苏
  • 细胞传代
  • 细胞冻存
  • 抗体验证结果
    • 品牌: ELEMok138cn太阳集团529
    • 商品名称: PRMT5 Knockout THP-1 Cell Pool
    • 商品编号: LM01300100462
    • Gene Symbol: PRMT5 HRMT1L5 IBP72 JBP1 SKB1
    • Ensembl ID: ENSG00000100462
    • Uniprot ID: O14744
    • 宿主细胞 / 类型: THP-1/人单核细胞白血病
    • NCBI Gene ID: 10419
    • 规格: 1×10^6 cells/ 冻存管
    • 筛选标记: N/A
    • 生长特性: 悬浮细胞
    • 培养条件: 37℃,5% CO2 的培养箱,1/2 到 1/4 传代
    • 倍增时间: ~24-36 hours
    • 生长培养基: RPMI-1640+10% FBS+0.05mM β-mercaptoethanol+1% P,S
    • 参考换液频率: 2-3 天换液
    • 支原体检测结果: 阴性
    • 敲除效率(Sanger测序): >70%
    • 蛋白质组验证结果: N/A
    • 抗体货号: 添加中
    • 目标基因介绍: Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA (PubMed:10531356, PubMed:11152681, PubMed:11747828, PubMed:12411503, PubMed:15737618, PubMed:17709427, PubMed:20159986, PubMed:20810653, PubMed:21258366, PubMed:21917714, PubMed:22269951, PubMed:21081503). Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles (PubMed:12411503, PubMed:11747828, PubMed:17709427). Methylates SUPT5H and may regulate its transcriptional elongation properties (PubMed:12718890). Mono- and dimethylates arginine residues of myelin basic protein (MBP) in vitro. May play a role in cytokine-activated transduction pathways. Negatively regulates cyclin E1 promoter activity and cellular proliferation. Methylates histone H2A and H4 'Arg-3' during germ cell development. Methylates histone H3 'Arg-8', which may repress transcription. Methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage (By similarity). Methylates RPS10. Attenuates EGF signaling through the MAPK1/MAPK3 pathway acting at 2 levels. First, monomethylates EGFR; this enhances EGFR 'Tyr-1197' phosphorylation and PTPN6 recruitment, eventually leading to reduced SOS1 phosphorylation (PubMed:21917714, PubMed:21258366). Second, methylates RAF1 and probably BRAF, hence destabilizing these 2 signaling proteins and reducing their catalytic activity (PubMed:21917714). Required for induction of E-selectin and VCAM-1, on the endothelial cells surface at sites of inflammation. Methylates HOXA9 (PubMed:22269951). Methylates and regulates SRGAP2 which is involved in cell migration and differentiation (PubMed:20810653). Acts as a transcriptional corepressor in CRY1-mediated repression of the core circadian component PER1 by regulating the H4R3 dimethylation at the PER1 promoter (By similarity). Methylates GM130/GOLGA2, regulating Golgi ribbon formation (PubMed:20421892). Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner (PubMed:25284789). Symmetrically methylates POLR2A, a modification that allows the recruitment to POLR2A of proteins including SMN1/SMN2 and SETX. This is required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination (PubMed:26700805). Along with LYAR, binds the promoter of gamma-globin HBG1/HBG2 and represses its expression (PubMed:25092918). Symmetrically methylates NCL (PubMed:21081503). Methylates TP53; methylation might possibly affect TP53 target gene specificity (PubMed:19011621). Involved in spliceosome maturation and mRNA splicing in prophase I spermatocytes through the catalysis of the symmetrical arginine dimethylation of SNRPB (small nuclear ribonucleoprotein-associated protein) and the interaction with tudor domain-containing protein TDRD6 (By similarity).
    • 细胞开发路径: 采用CRISPR-RNP方法生成稳定KO Cell Pool;Sanger 测序结果显示KO Cell Pool敲除效率>70%。
    • 应用: 高敲除效率的基因敲除细胞池(KO Cell Pool),特别适用于初步功能分析、复杂疾病模型的开发、精准药物筛选以及广泛的基因发现研究。KO pool能够无需繁琐的单克隆挑选过程,直接应用于多种类型的测定和分析,大幅提升实验效率。
    关键词:
    • PRMT5 HRMT1L5 IBP72 JBP1 SKB1
  • 01.  在 37℃水浴中预热完全培养基。
    02.  将冻存管在 37℃水浴中解冻 1-2 分钟。
    03.  将冻存管转移到生物安全柜中,并用 70% 乙醇擦拭表面。
    04.  拧开冻存管管盖,将细胞悬液轻轻转移到含有 9mL 完全培养基的无菌离心管中。
    05.  在室温下以 125g 离心 5-7 分钟,弃上清。
    06.  用 5mL 的完整培养基重悬细胞沉淀,将细胞悬液转移到 T25 培养瓶中。
    07.  将细胞转移到 37℃,5% CO2 的培养箱中培养。
    08.  参考传代比例:1/2 到 1/4 传代,2-3 天长满。

  • 01.  待培养瓶中细胞汇合度至 80%-90% 以上,可进行细胞传代。
    02.  将培养基、PBS、胰酶(0.25%Trypsin_EDTA Gibco 25200-056) 等从 4℃冰箱中拿出, 置于 37℃水浴中温度接近 37℃时取出并在瓶子表面喷洒 75% 酒精后置于生物安全柜中。

    03.  从培养箱中取出待传代的培养瓶,瓶身喷洒 75% 酒精后置于生物安全柜中。
    04.  为避免冲散细胞,沿培养瓶上壁 PBS 润洗细胞,清洗细胞后弃去,T25 加 2mL。
    05.  加入对应体积的胰酶(T75 加 1.5mL, T25 加 0.5mL)  ,并轻轻晃动瓶身使胰酶平铺满细胞 底部。可根据实际情况适当增加或减少用量。约 1-2min 后大部分细胞脱落时,加入对应体积的完全培养基终止消化,并用 5mL 移液管轻轻吹打至细胞全部脱落。
    06.  将细胞悬液转移至 15mL 离心管,悬液 300g 离心 5min,弃上清。
    07.  移取 5mL 完全培养基重悬细胞,按需求调整接种比例,并补充培养瓶中完全培养基,T75 加至 13-15mL,T25 加至 5mL,加 1% 双抗。
    08.  盖上瓶盖拧紧后轻轻晃动瓶身,使细胞混合均匀后置于 37℃,5% CO2 培养箱中。

  • 01.  准备冻存液,并提前预冷。
    02.  确保待冻存的细胞满足冻存要求,用显微镜检查以下状态:健康的外观及形态特征、所处生 长周期(对数晚期)、无污染或衰退迹象。
    03.  对细胞进行消化及离心处理(具体步骤参考传代培养流程)
    04.  按照每管 1mL 的量添加冻存液重悬细胞,吹打均匀后分装至冻存管。
    05.  将细胞放在程序降温盒中,在 -80℃冰箱中冷冻。
    06.  后续将细胞转移到液氮罐中,以便长期储存。

  • 抗体验证中

产品类型: 基因敲除细胞池(蛋白降解药物相关靶点)

细胞系信息

Gene Symbol

PRMT5 HRMT1L5 IBP72 JBP1 SKB1

NCBI Gene ID

10419

Ensembl ID

ENSG00000100462

Uniprot ID

O14744

筛选标记

N/A

宿主细胞 / 类型

THP-1/人单核细胞白血病

规格

1×10^6 cells/ 冻存管

生长培养基

RPMI-1640+10% FBS+0.05mM β-mercaptoethanol+1% P,S

生长特性

悬浮细胞

培养条件

37℃,5% CO2 的培养箱,1/2 到 1/4 传代

倍增时间

~24-36 hours

参考换液频率

2-3 天换液

支原体检测结果

阴性

敲除验证

敲除效率(Sanger测序)

>70%

蛋白质组验证结果

N/A

抗体货号

添加中

抗体验证结果

抗体验证中

细胞系说明

目标基因介绍

Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA (PubMed:10531356, PubMed:11152681, PubMed:11747828, PubMed:12411503, PubMed:15737618, PubMed:17709427, PubMed:20159986, PubMed:20810653, PubMed:21258366, PubMed:21917714, PubMed:22269951, PubMed:21081503). Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles (PubMed:12411503, PubMed:11747828, PubMed:17709427). Methylates SUPT5H and may regulate its transcriptional elongation properties (PubMed:12718890). Mono- and dimethylates arginine residues of myelin basic protein (MBP) in vitro. May play a role in cytokine-activated transduction pathways. Negatively regulates cyclin E1 promoter activity and cellular proliferation. Methylates histone H2A and H4 'Arg-3' during germ cell development. Methylates histone H3 'Arg-8', which may repress transcription. Methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage (By similarity). Methylates RPS10. Attenuates EGF signaling through the MAPK1/MAPK3 pathway acting at 2 levels. First, monomethylates EGFR; this enhances EGFR 'Tyr-1197' phosphorylation and PTPN6 recruitment, eventually leading to reduced SOS1 phosphorylation (PubMed:21917714, PubMed:21258366). Second, methylates RAF1 and probably BRAF, hence destabilizing these 2 signaling proteins and reducing their catalytic activity (PubMed:21917714). Required for induction of E-selectin and VCAM-1, on the endothelial cells surface at sites of inflammation. Methylates HOXA9 (PubMed:22269951). Methylates and regulates SRGAP2 which is involved in cell migration and differentiation (PubMed:20810653). Acts as a transcriptional corepressor in CRY1-mediated repression of the core circadian component PER1 by regulating the H4R3 dimethylation at the PER1 promoter (By similarity). Methylates GM130/GOLGA2, regulating Golgi ribbon formation (PubMed:20421892). Methylates H4R3 in genes involved in glioblastomagenesis in a CHTOP- and/or TET1-dependent manner (PubMed:25284789). Symmetrically methylates POLR2A, a modification that allows the recruitment to POLR2A of proteins including SMN1/SMN2 and SETX. This is required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination (PubMed:26700805). Along with LYAR, binds the promoter of gamma-globin HBG1/HBG2 and represses its expression (PubMed:25092918). Symmetrically methylates NCL (PubMed:21081503). Methylates TP53; methylation might possibly affect TP53 target gene specificity (PubMed:19011621). Involved in spliceosome maturation and mRNA splicing in prophase I spermatocytes through the catalysis of the symmetrical arginine dimethylation of SNRPB (small nuclear ribonucleoprotein-associated protein) and the interaction with tudor domain-containing protein TDRD6 (By similarity).

细胞开发路径

采用CRISPR-RNP方法生成稳定KO Cell Pool;Sanger 测序结果显示KO Cell Pool敲除效率>70%。

应用

高敲除效率的基因敲除细胞池(KO Cell Pool),特别适用于初步功能分析、复杂疾病模型的开发、精准药物筛选以及广泛的基因发现研究。KO pool能够无需繁琐的单克隆挑选过程,直接应用于多种类型的测定和分析,大幅提升实验效率。

细胞培养说明

细胞复苏

01.  在 37℃水浴中预热完全培养基。
02.  将冻存管在 37℃水浴中解冻 1-2 分钟。
03.  将冻存管转移到生物安全柜中,并用 70% 乙醇擦拭表面。
04.  拧开冻存管管盖,将细胞悬液轻轻转移到含有 9mL 完全培养基的无菌离心管中。
05.  在室温下以 125g 离心 5-7 分钟,弃上清。
06.  用 5mL 的完整培养基重悬细胞沉淀,将细胞悬液转移到 T25 培养瓶中。
07.  将细胞转移到 37℃,5% CO2 的培养箱中培养。
08.  参考传代比例:1/2 到 1/4 传代,2-3 天长满。

细胞传代

01.  待培养瓶中细胞汇合度至 80%-90% 以上,可进行细胞传代。
02.  将培养基、PBS、胰酶(0.25%Trypsin_EDTA Gibco 25200-056) 等从 4℃冰箱中拿出, 置于 37℃水浴中温度接近 37℃时取出并在瓶子表面喷洒 75% 酒精后置于生物安全柜中。

03.  从培养箱中取出待传代的培养瓶,瓶身喷洒 75% 酒精后置于生物安全柜中。
04.  为避免冲散细胞,沿培养瓶上壁 PBS 润洗细胞,清洗细胞后弃去,T25 加 2mL。
05.  加入对应体积的胰酶(T75 加 1.5mL, T25 加 0.5mL)  ,并轻轻晃动瓶身使胰酶平铺满细胞 底部。可根据实际情况适当增加或减少用量。约 1-2min 后大部分细胞脱落时,加入对应体积的完全培养基终止消化,并用 5mL 移液管轻轻吹打至细胞全部脱落。
06.  将细胞悬液转移至 15mL 离心管,悬液 300g 离心 5min,弃上清。
07.  移取 5mL 完全培养基重悬细胞,按需求调整接种比例,并补充培养瓶中完全培养基,T75 加至 13-15mL,T25 加至 5mL,加 1% 双抗。
08.  盖上瓶盖拧紧后轻轻晃动瓶身,使细胞混合均匀后置于 37℃,5% CO2 培养箱中。

细胞冻存

01.  准备冻存液,并提前预冷。
02.  确保待冻存的细胞满足冻存要求,用显微镜检查以下状态:健康的外观及形态特征、所处生 长周期(对数晚期)、无污染或衰退迹象。
03.  对细胞进行消化及离心处理(具体步骤参考传代培养流程)
04.  按照每管 1mL 的量添加冻存液重悬细胞,吹打均匀后分装至冻存管。
05.  将细胞放在程序降温盒中,在 -80℃冰箱中冷冻。
06.  后续将细胞转移到液氮罐中,以便长期储存。

XML 地图